Supplemental material
Drug Delivery
Volume 25, 2018 - Issue 1
Open access
2,678
Views
29
CrossRef citations to date
0
Altmetric
Research Article
AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells
Diana RafaelResearch Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia, Universidade de Lisboa (iMed.ULisboa), Lisbon, Portugal; ;Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
, Petra GenerDrug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; ;Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain; View further author information
, Fernanda AndradeNetworking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain; View further author information
, Joaquin Seras-FranzosoDrug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
, Sara MonteroDrug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
, Yolanda FernándezDrug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; ;Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain; ;Functional Validation and Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
, Manuel HidalgoDivision of Hematology and Oncology, Rosenberg Clinical Cancer Center Beth Israel Deaconess Medical Center, Boston, MA, USA; View further author information
, Diego ArangoBiomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
, Joan SayósImmune Regulation and Immunotherapy, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, SpainView further author information
, Helena F. FlorindoResearch Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia, Universidade de Lisboa (iMed.ULisboa), Lisbon, Portugal; View further author information
, Ibane AbasoloDrug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; ;Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain; ;Functional Validation and Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
, Simó Schwartz JrDrug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; ;Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza, Spain; Correspondence[email protected]
http://orcid.org/0000-0001-8297-7971View further author information
& http://orcid.org/0000-0001-8297-7971View further author information
Mafalda VideiraResearch Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia, Universidade de Lisboa (iMed.ULisboa), Lisbon, Portugal; Correspondence[email protected]
View further author information
show allView further author information
Pages 961-972
|
Received 01 Feb 2018, Accepted 02 Apr 2018, Published online: 18 Apr 2018
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.